

Michael H Wilke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2535355/publications.pdf>

Version: 2024-02-01

11
papers

275
citations

1307594

7
h-index

1372567

10
g-index

13
all docs

13
docs citations

13
times ranked

456
citing authors

#	ARTICLE	IF	CITATIONS
1	Calculated parenteral initial treatment of bacterial infections: Economic aspects of antibiotic treatment. <i>GMS Infectious Diseases</i> , 2020, 8, Doc03.	0.8	0
2	Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data. <i>GMS Infectious Diseases</i> , 2019, 7, Doc03.	0.8	9
3	Treatment of MRSA pneumonia: Clinical and economic comparison of linezolid vs. vancomycin - a retrospective analysis of medical charts and re-imburement data of real-life patient populations. <i>GMS Infectious Diseases</i> , 2017, 5, Doc02.	0.8	1
4	Invasive Fungal Infections in Infants – Focus on Anidulafungin. <i>Clinical Medicine Insights Pediatrics</i> , 2013, 7, CMPed.S8028.	1.4	6
5	Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. <i>Infection and Drug Resistance</i> , 2013, 7, 1.	2.7	40
6	Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature. <i>European Journal of Medical Research</i> , 2011, 16, 180.	2.2	35
7	Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy. <i>European Journal of Medical Research</i> , 2011, 16, 315.	2.2	54
8	Pharmaco-economic evaluation of antibiotic therapy strategies in DRG-based healthcare systems - a new approach. <i>European Journal of Medical Research</i> , 2010, 15, 564.	2.2	5
9	Multiresistant bacteria and current therapy - the economical side of the story. <i>European Journal of Medical Research</i> , 2010, 15, 571.	2.2	30
10	The cost of resistance: incremental cost of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in German hospitals. <i>European Journal of Health Economics</i> , 2009, 10, 287-297.	2.8	76
11	Carbapenem-resistant gram-negative bacteria in Germany: incidence and distribution among specific infections and mortality: an epidemiological analysis using real-world data. <i>Infection</i> , 0, , .	4.7	3